潤藥(03320.HK)旗下「生物醫藥創新抗體藥物研發」入選國資委首批央企AI戰略性高價值場景
華潤醫藥(03320.HK)宣佈,集團旗下華潤生物醫藥申報的「生物醫藥創新抗體藥物研發」,入選國務院國資委發佈的首批40項中央企業人工智能戰略性高價值場景,標誌着集團在人工智能與生物醫藥領域融合創新的探索與實踐獲得高度認可。
「生物醫藥創新抗體藥物研發」場景深度融合了人工智能技術與抗體藥物研發流程,針對傳統抗體藥物研發週期長、成本高、成功率低等痛點問題,藉助人工智能強大的數據處理和分析能力,對抗體的結構設計、活性預測、親和力優化等環節進行精準模擬與篩選,極大提升了研發效率,有望加速創新抗體藥物的上市進程。
近年來,集團始終將科技創新視爲驅動產業升級的核心引擎,未來將不斷加大在人工智能技術與生物醫藥研發融合領域的投入,積極開展技術創新與應用拓展,利用AI+CADD技術提高藥物發現的效率,降低研發成本,加速藥物進入臨牀的過程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.